GlassScriptPhysician profile
Donna Young
NPI 1881256923
$3,261.04
in general payments reported to CMS, 2019-2025
27 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $869 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.04 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $390.51 | 2024-2025 | |
| Neurelis, INC. | $375.72 | 2024-2025 | Valtoco |
| Tg Therapeutics, INC. | $372.04 | 2024-2025 | |
| Lundbeck LLC | $234.76 | 2024-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $187.43 | 2025 | Wainua |
| Biogen, INC. | $181.13 | 2024-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $176.42 | 2025 | |
| Lilly USA, LLC | $173.93 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $126.96 | 2025 | |
| Janssen Biotech, INC. | $120.40 | 2025 | |
| Abbvie INC. | $103.46 | 2025 | |
| Argenx US, INC. | $102.12 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $96.41 | 2024-2025 | Gamunex-C |
| Ani Pharmaceuticals, INC. | $95.44 | 2025 | Purified Cortrophin Gel |
| Csl Behring | $88.20 | 2024-2025 | Hizentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.07 | 2024-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $73.13 | 2024 | Zeposia |
| Ucb, INC. | $62.49 | 2024-2025 | Rystiggo, Fintepla, Nayzilam |
| Sk Life Science, INC. | $46.79 | 2024 | |
| Amgen INC. | $34.09 | 2025 | Uplizna |
| Celgene Corporation | $33.57 | 2024 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $23.66 | 2025 | |
| Livanova USA, INC. | $23.14 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $18.71 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.68 | 2024 | Ajovy |
| Genentech USA, INC. | $14.14 | 2025 | Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.